A 52-Week Open-Label (Sponsor-Blind), Randomized, Active-Controlled, P
Research payments
$1,002,378
Through program year 2023, $1,002,378 in research payments was reported against A 52-Week Open-Label (Sponsor-Blind), Randomized, Active-Controlled, P, across 519 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $213 | 1 |
| 2022 | Research | $48,463 | 23 |
| 2021 | Research | $367,651 | 242 |
| 2020 | Research | $148,511 | 72 |
| 2019 | Research | $437,539 | 181 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Naheed Ansari Bronx, NY Named on 30 payments
- Matthew Abramowitz Bronx, NY Named on 20 payments
- Jorge Posada Coral Gables, FL Named on 18 payments
- Shahabul Arfeen Munster, IN Named on 18 payments
- Laura Mulloy Augusta, GA Named on 18 payments
- Ahmed Awad Kansas City, MO Named on 17 payments
- Daphne Knicely Fishersville, VA Named on 16 payments
- Kenneth Choi Merrillville, IN Named on 14 payments
- Daniel Coyne Saint Louis, MO Named on 12 payments
- Ramon Guadiz Downey, CA Named on 12 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.